Portfolio company
Heidelberg Pharma AG
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops antibody-drug conjugates for oncology patients using proprietary toxin technology to target and eliminate cancer cells.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Heidelberg Pharma
This biopharmaceutical company develops antibody drug conjugates for cancer treatment, serving pharmaceutical partners and patients through its proprietary toxin-based technology platform.
Pyxisoncology
The company develops antibody-drug conjugates and monoclonal antibody immunotherapies for patients with difficult-to-treat cancers.
Alphina Therapeutics
This biotechnology company develops antibody-drug conjugates with novel payloads to treat solid tumours for healthcare providers and cancer patients.
TORL BioTherapeutics
This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.
Adcytherix
This biopharmaceutical company develops novel antibody-drug conjugates to treat various forms of cancer for patients with high unmet clinical needs.
Araris Biotech
This company develops antibody-drug conjugate linker technology and targeted cancer therapies for pharmaceutical partners and patients.
Full-Life Technologies
This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.
Adcendo
This clinical-stage biotechnology company develops antibody-drug conjugates to treat patients with various types of cancer and high unmet medical needs.